Modi Dipenkumar, Potugari Bindu, Uberti Joseph
Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, 4100 John R, HW04HO, Detroit, MI 48201, USA.
Department of Hematology and Oncology, St Joseph Mercy Health System, Ann Arbor, MI 48201, USA.
Cancers (Basel). 2021 Nov 20;13(22):5827. doi: 10.3390/cancers13225827.
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease. B-cell receptor (BCR) pathway is essential for malignant B-cell growth, survival, and proliferation. Various immune cells, including T-cells and macrophages in the tumor microenvironment (TME) contribute to tumor cell survival and pathogenesis of chemo-resistance. The presence of many targets on the malignant B-cells and in the TME has led to emergence of novel therapeutic agents. Stem cell transplant is the oldest treatment modality leveraging immune system in DLBCL. Subsequently, CD20 targeting monoclonal antibody and chimeric antigen receptor (CAR) T-cell therapy changed the treatment landscape of DLBCL. Recently, multiple novel immunotherapeutic agents have been added in the armamentarium for the management of DLBCL, and many are under development. In this review article, we will review latest updates of immunotherapeutic agents in the management of DLBCL.
弥漫性大B细胞淋巴瘤（DLBCL）是一种异质性疾病。B细胞受体（BCR）通路对于恶性B细胞的生长、存活和增殖至关重要。肿瘤微环境（TME）中的各种免疫细胞，包括T细胞和巨噬细胞，都有助于肿瘤细胞的存活和化疗耐药的发生机制。恶性B细胞和TME中存在许多靶点，导致了新型治疗药物的出现。干细胞移植是DLBCL中利用免疫系统的最古老治疗方式。随后，靶向CD20的单克隆抗体和嵌合抗原受体（CAR）T细胞疗法改变了DLBCL的治疗格局。最近，多种新型免疫治疗药物已被纳入DLBCL治疗的武器库，并且许多药物正在研发中。在这篇综述文章中，我们将回顾DLBCL治疗中免疫治疗药物的最新进展。
